Physician profile
Wayne C Barish
NPI 1346278256
$3,931.25
in general payments reported to CMS, 2019-2025
27 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $93.21 · 2021: $415 · 2022: $327 · 2023: $1,377 · 2024: $389 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Travel and Lodging: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.10 |
| Travel and Lodging | $949.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,242.98 | 2020-2023 | Lensx, Clareon, Rocklatan |
| Abbvie INC. | $377.03 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $283.27 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $258.74 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $213.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $141.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $136.34 | 2019-2023 | |
| Beaver-Visitec International, INC. | $131.82 | 2022 | |
| Dompe US, INC. | $105.50 | 2021-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $102.17 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $99.29 | 2023-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.29 | 2020-2021 | |
| Allergan, INC. | $81.79 | 2019-2021 | |
| Rxsight INC | $81.46 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Harrow Eye, LLC | $72.85 | 2025 | Vevye |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $71.72 | 2025 | Iluvien, Yutiq |
| Glaukos Corporation | $70.72 | 2025 | Idosetr, Istent Infinite |
| Astellas Pharma US INC | $53.76 | 2024-2025 | Izervay |
| Genentech USA, INC. | $49.99 | 2025 | Vabysmo |
| Kala Pharmaceuticals, INC. | $45.50 | 2019-2021 | |
| Oyster Point Pharma, INC. | $43.68 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $42.43 | 2021-2022 | |
| Sight Sciences, INC. | $40.67 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Quidel Corporation | $37.16 | 2021 | |
| Biotissue Holdings INC. | $20.36 | 2024 | |
| Rayner Intraocular Lenses Limited | $19.69 | 2025 | Rayone Emv, Rayone Aspheric, Rayner Cataract Set 1 |
| Shire North American Group INC | $16.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Barish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.